

# K Rajender Reddy

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4740700/k-rajender-reddy-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

329  
papers

33,559  
citations

76  
h-index

181  
g-index

348  
ext. papers

38,115  
ext. citations

8.3  
avg, IF

7.01  
L-index

#	Paper	IF	Citations
329	Statin exposure is associated with reduced development of acute on chronic liver failure in a veterans affairs cohort.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	1
328	Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY).. <i>Open Forum Infectious Diseases</i> , <b>2022</b> , 9, ofab605	1	1
327	Gene therapy: Practical aspects of implementation.. <i>Haemophilia</i> , <b>2022</b> , 28 Suppl 4, 44-52	3.3	1
326	Con: Patients With Acute-on-Chronic Liver Failure Should Not Receive Priority on the Waiting List. <i>Clinical Liver Disease</i> , <b>2022</b> , 19, 207-212	2.2	
325	Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 1472-1480	6.1	2
324	The Mucosally-Adherent Rectal Microbiota Contains Features Unique to Alcohol-Related Cirrhosis. <i>Gut Microbes</i> , <b>2021</b> , 13, 1987781	8.8	3
323	In the Era of Direct-Acting Antivirals, Liver Transplant Delisting Due to Clinical Improvement for Hepatitis C Remains Infrequent. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2389-2397.e2	6.9	4
322	Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 66, 3612-3618	4	5
321	Progression of Stage 2 and 3 Acute Kidney Injury in Patients With Decompensated Cirrhosis and Ascites. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1661-1669.e2	6.9	4
320	A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2597-2605.e4	6.9	22
319	Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 818-828	59.2	55
318	Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVID-19: A Multicenter Cohort. <i>Liver Transplantation</i> , <b>2021</b> , 27, 1343-1347	4.5	8
317	Willingness to participate in research among black patients with liver disease: A national cross-sectional study. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 982-993	3.4	0
316	Black Race Is Associated With Higher Rates of Early-Onset End-Stage Renal Disease and Increased Mortality Following Liver Transplantation. <i>Liver Transplantation</i> , <b>2021</b> , 27, 1154-1164	4.5	4
315	COVID-19 Vaccine Perceptions Among Patients With Chronic Disease in a Large Gastroenterology and Hepatology Practice. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 1345-1349	0.7	3
314	Multigene Panel Testing in Individuals With Hepatocellular Carcinoma Identifies Pathogenic Germline Variants. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	2
313	The Evolving Challenge of Infections in Cirrhosis. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 2317-2330	59.2	14

312	Occult Hepatocellular Carcinoma Associated With Transjugular Intrahepatic Portosystemic Shunts in Liver Transplant Recipients. <i>Liver Transplantation</i> , <b>2021</b> , 27, 1248-1261	4.5	1
311	Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis. <i>Hepatology</i> , <b>2021</b> , 74, 2699-2713	11.2	8
310	Acute Liver Failure Etiology Is an Independent Predictor of Waitlist Outcome but Not Posttransplantation Survival in a National Cohort. <i>Liver Transplantation</i> , <b>2021</b> ,	4.5	2
309	Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Comorbid Diseases. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 996-1008.e6	6.9	9
308	Insurance Status But Not Race and Ethnicity Are Associated With Outcomes in a Large Hospitalized Cohort of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 565-572.e5	6.9	3
307	Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. <i>Gut</i> , <b>2021</b> , 70, 531-536	19.2	94
306	Reply to Roussel et al. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, e929	11.6	
305	Transplant center experience influences spontaneous survival and waitlist mortality in acute liver failure: An analysis of the UNOS database. <i>American Journal of Transplantation</i> , <b>2021</b> , 21, 1092-1099	8.7	3
304	Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C-Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis. <i>Liver Transplantation</i> , <b>2021</b> , 27, 568-579	4.5	3
303	Hepatitis C viraemic organs in solid organ transplantation. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 716-733	13.4	6
302	Non-alcoholic fatty liver disease: Not time for an obituary just yet!. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 972-974	3.4	12
301	Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United States. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, e558-e565	11.6	61
300	Weight Loss and Weight Regain in Usual Clinical Practice: Results From the TARGET-NASH Observational Cohort. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	7
299	Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. <i>Liver International</i> , <b>2021</b> , 41, 692-704	7.9	2
298	Impact of Donor and Recipient Clinical Characteristics and Hepatic Histology on Steatosis/Fibrosis Following Liver Transplantation. <i>Transplantation</i> , <b>2021</b> ,	1.8	1
297	Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study. <i>Hepatology Communications</i> , <b>2021</b> , 5, 938-946	6	4
296	Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	6
295	REPLY. <i>Hepatology</i> , <b>2021</b> , 74, 2916-2917	11.2	

294	A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. <i>Hepatology</i> , <b>2021</b> , 74, 2952-2964	11.2	0
293	American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. <i>Hepatology</i> , <b>2021</b> , 74, 1049-1064	11.3	47
292	COVID-19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later. <i>Journal of Viral Hepatitis</i> , <b>2021</b> ,	3.4	4
291	Inpatient Frailty Assessment Is Feasible and Predicts Nonhome Discharge and Mortality in Decompensated Cirrhosis. <i>Liver Transplantation</i> , <b>2021</b> , 27, 1711-1722	4.5	1
290	Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	10
289	Letter: patients who have both sarcopenia and frailty have similar prognosis to those with either condition separately-authors Reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 983-984	6.1	0
288	A pragmatic outreach pilot to understand and overcome barriers to COVID-19 vaccination in abdominal organ transplant. <i>Transplant Infectious Disease</i> , <b>2021</b> , 23, e13722	2.7	4
287	The Prediction of In-Hospital Mortality in Decompensated Cirrhosis with Acute-on-Chronic Liver Failure. <i>Liver Transplantation</i> , <b>2021</b> ,	4.5	3
286	A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC. <i>Hepatology Communications</i> , <b>2021</b> , 5, 538-547	6	1
285	Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed?. <i>Clinics in Liver Disease</i> , <b>2020</b> , 24, 317-333	4.6	14
284	A local response to COVID-19 for advanced liver disease: Current model of care, challenges and opportunities. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 708-709	13.4	8
283	Oral Contraceptive-Induced Hepatic Sinusoidal Dilatation and Potential Implications for Living Donor Liver Transplantation: A Reason for Nonuse of Right Lobe Grafts. <i>Liver Transplantation</i> , <b>2020</b> , 26, 722-725	4.5	0
282	Underutilization of Hospice in Inpatients with Cirrhosis: The NACSELD Experience. <i>Digestive Diseases and Sciences</i> , <b>2020</b> , 65, 2571-2579	4	5
281	Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 1222-1233	3.4	0
280	Model for End-Stage Liver Disease-Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease. <i>Hepatology</i> , <b>2020</b> , 72, 1747-1757	11.2	20
279	Nonpharmacologic Management of Hepatic Encephalopathy: An Update. <i>Clinics in Liver Disease</i> , <b>2020</b> , 24, 243-261	4.6	3
278	Screening for hepatocellular carcinoma in viral liver disease: any new biomarkers on the horizon? <b>2020</b> , 15-18		
277	Hepatitis C virus and injecting drug use: what are the challenges? <b>2020</b> , 78-81		

276 Treatment of hepatitis C in children **2020**, 94-96

275 Drug-drug interactions with direct-acting antivirals: when do we need to care? **2020**, 86-93

274 Is ribavirin alive or dead in the current era of HCV therapy? **2020**, 35-40

273 Rethinking the inactive carrier state: management of patients with low-replicative HBeAg-negative chronic hepatitis B and normal liver enzymes **2020**, 150-155

272 Treatment of hepatitis B in children **2020**, 164-168

271 Do we need expert hepatitis C virus treaters or are amateur treaters good enough? **2020**, 201-207

270 Generic direct-acting antiviral agents: do they work well? **2020**, 66-73

269 Hepatitis C and hepatitis B coinfection **2020**, 182-188

1

268 Acute hepatitis C: treat immediately or give a chance to spontaneously clear? **2020**, 25-34

267 Does directly acting antiviral therapy improve quality of life? **2020**, 54-58

266 Treatment of hepatitis C virus in renal disease: can we use all the drugs without additional monitoring? **2020**, 48-53

265 Morbid obesity and hepatitis C: treat as normal or are there additional issues to consider? **2020**, 59-65

264 Is hepatocellular carcinoma risk impacted favorably or unfavorably by hepatitis C virus therapy with direct-acting antivirals? **2020**, 231-237

263 Impact and management of patients with multiple hepatitis C virus genotypes **2020**, 74-77

262 Hepatitis B e antigen-positive chronic hepatitis B infection with minimal changes on liver biopsy: what to do next **2020**, 156-159

261 Realistic estimates of hepatitis C virus and hepatitis B virus disease burden **2020**, 19-24

260 Epstein-Barr Virus and Cytomegalovirus Infections of the Liver. *Gastroenterology Clinics of North America*, **2020**, 49, 331-346

4-4 7

259 Fungal and Parasitic Infections of the Liver. *Gastroenterology Clinics of North America*, **2020**, 49, 379-410

4-4 2

258	DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 540-548	13.4	45
257	Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 64-77	6.1	58
256	Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. <i>Journal of General Internal Medicine</i> , <b>2020</b> , 35, 1011-1020	4	8
255	Liver Injury in Patients With Cholestatic Liver Disease Treated With Obeticholic Acid. <i>Hepatology</i> , <b>2020</b> , 71, 1511-1514	11.2	24
254	Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfecting patients (ANRS[C]O13 HEPAVIH)". <i>Journal of Hepatology</i> , <b>2020</b> , 72, 592-593	13.4	
253	Predictors, Presentation, and Treatment Outcomes of Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Large Single Center Experience. <i>Journal of Clinical and Experimental Hepatology</i> , <b>2020</b> , 10, 304-315	4.1	9
252	Reply to: "HCV treatment in cirrhotic patients: Should we use a different approach for patients awaiting a liver transplant". <i>Journal of Hepatology</i> , <b>2020</b> , 73, 985-986	13.4	
251	Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis. <i>Gastroenterology</i> , <b>2020</b> , 159, 1715-1730.e12	13.3	24
250	Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. <i>Hepatology</i> , <b>2020</b> , 72, 1819-1837	11.2	12
249	Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 468-476.e11	6.9	10
248	Hospitalized Women With Cirrhosis Have More Nonhepatic Comorbidities and Associated Complications Than Men. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 3046-3048	6.9	3
247	Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. <i>Hepatology</i> , <b>2020</b> , 72, 287-304	11.2	271
246	While direct-acting antivirals are effective, are there any unique safety considerations? <b>2020</b> , 97-105		1
245	SARS-CoV-2 and the Liver: Considerations in Hepatitis B and Hepatitis C Infections. <i>Clinical Liver Disease</i> , <b>2020</b> , 15, 191-194	2.2	16
244	Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 492-505	6.1	10
243	Hepatitis C virus therapy in advanced liver disease: Outcomes and challenges. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 642-650	5.3	14
242	Use of HCV-infected organs in solid organ transplantation: An ethical challenge but plausible option. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 1362-1371	3.4	10
241	Early emergence of anti-HCV antibody implicates donor origin in recipients of an HCV-infected organ. <i>American Journal of Transplantation</i> , <b>2019</b> , 19, 2525-2532	8.7	9

240	High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 1186-1199	3.4	13
239	Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 486-497	13.4	27
238	Infections in Cirrhosis. <i>Current Treatment Options in Gastroenterology</i> , <b>2019</b> , 17, 254-270	2.5	15
237	Direct-Acting Oral Anticoagulants (DOACs) in Cirrhosis and Cirrhosis-Associated Portal Vein Thrombosis. <i>Seminars in Liver Disease</i> , <b>2019</b> , 39, 195-208	7.3	24
236	Hepatic Manifestations of Lymphoproliferative Disorders. <i>Clinics in Liver Disease</i> , <b>2019</b> , 23, 293-308	4.6	2
235	Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. <i>Liver Transplantation</i> , <b>2019</b> , 25, 870-880	4.5	22
234	Importance of Hepatitis C Virus RNA Testing in Patients with Suspected Drug-Induced Liver Injury. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 2645-2652	4	5
233	Characterization of early hepatic injury in HCV-negative recipients of HCV-infected kidneys. <i>Clinical Transplantation</i> , <b>2019</b> , 33, e13494	3.8	2
232	Outcomes After Listing for Liver Transplant in Patients With Acute-on-Chronic Liver Failure: The Multicenter North American Consortium for the Study of End-Stage Liver Disease Experience. <i>Liver Transplantation</i> , <b>2019</b> , 25, 571-579	4.5	30
231	Transplanting hepatitis C virus-infected hearts into uninfected recipients: A single-arm trial. <i>American Journal of Transplantation</i> , <b>2019</b> , 19, 2533-2542	8.7	64
230	Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension. <i>Hepatology</i> , <b>2019</b> , 69, 717-728	11.2	49
229	Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis. <i>Hepatology Communications</i> , <b>2019</b> , 3, 1388-1399	6	5
228	Reply. <i>Liver Transplantation</i> , <b>2019</b> , 25, 1586-1587	4.5	
227	Pharmacologic Management of Portal Hypertension. <i>Clinics in Liver Disease</i> , <b>2019</b> , 23, 713-736	4.6	6
226	When (and When Not) to Treat Patients With HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2644-2647	6.9	1
225	Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. <i>Gastroenterology</i> , <b>2019</b> , 157, 1506-1517.e1	13.3	19
224	Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 82, 71-80	3.1	10
223	National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2019</b> , 30, 1939-1951	12.7	43

222	Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 1091-1100	0.7	15
221	Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience. <i>Journal of Clinical and Experimental Hepatology</i> , <b>2019</b> , 9, 283-293	4.1	7
220	GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2019</b> , 28, 531-538	4	64
219	Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute® Early Detection Research Network. <i>Contemporary Clinical Trials</i> , <b>2019</b> , 76, 49-54	2.3	8
218	Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 756-765.e3	6.9	50
217	Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1278-1287	6.1	39
216	Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. <i>Hepatology</i> , <b>2018</b> , 68, 1298-1307	11.2	121
215	Acute-on-Chronic Liver Failure: Getting Ready for Prime Time?. <i>Hepatology</i> , <b>2018</b> , 68, 1621-1632	11.2	65
214	Acetaminophen (APAP or N-Acetyl-p-Aminophenol) and Acute Liver Failure. <i>Clinics in Liver Disease</i> , <b>2018</b> , 22, 325-346	4.6	70
213	Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?. <i>Journal of Clinical and Experimental Hepatology</i> , <b>2018</b> , 8, 81-94	4.1	14
212	Patterns of Discordance Between Pretransplant Imaging Stage of Hepatocellular Carcinoma and Posttransplant Pathologic Stage: A Contemporary Appraisal of the Milan Criteria. <i>Transplantation</i> , <b>2018</b> , 102, 648-655	1.8	18
211	Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 415-423	1.6	14
210	NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. <i>Hepatology</i> , <b>2018</b> , 67, 2367-2374	11.2	122
209	Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort. <i>Hepatology Communications</i> , <b>2018</b> , 2, 354-363	6	9
208	Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens. <i>Liver International</i> , <b>2018</b> , 38, 821-833	7.9	17
207	Letter: direct-acting anti-viral (DAA) therapy needs strong safety and efficacy check-authors®reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 235-236	6.1	
206	Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial. <i>Annals of Internal Medicine</i> , <b>2018</b> , 169, 273-281	8	139
205	A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. <i>PLoS ONE</i> , <b>2018</b> , 13, e0196908	3.7	16



204	Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 559-565	18.8	15
203	Sustained Virological Response Is Associated with a Decreased Risk of Posttransplant Diabetes Mellitus in Liver Transplant Recipients with Hepatitis C-Related Liver Disease. <i>Liver Transplantation</i> , <b>2018</b> , 24, 1665-1672	4.5	7
202	Reply. <i>Hepatology</i> , <b>2018</b> , 68, 2046-2048	11.2	
201	Neutrophil-to-Lymphocyte Ratio Associates Independently With Mortality in Hospitalized Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1786-1791.e1	6.9	29
200	HBV-Associated Acute Liver Failure After Immunosuppression and Risk of Death. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 113-122	6.9	23
199	Chronic hepatitis C and chronic kidney disease: Advances, limitations and uncharted territories. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 442-453	3.4	26
198	Heat stroke leading to acute liver injury & failure: A case series from the Acute Liver Failure Study Group. <i>Liver International</i> , <b>2017</b> , 37, 509-513	7.9	30
197	Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 1354-1361	4	20
196	Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2017</b> , 26, 1085-1092	4	27
195	Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. <i>Hepatology</i> , <b>2017</b> , 66, 1090-1101	11.2	127
194	Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 927-935	3.4	27
193	Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. <i>Contemporary Clinical Trials</i> , <b>2017</b> , 57, 58-68	2.3	10
192	Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1103-1110	0.7	40
191	The Natural History of Severe Acute Liver Injury. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1389-1396	13.96	65
190	Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 2394-2395	59.2	251
189	Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. <i>Transplant International</i> , <b>2017</b> , 30, 196-208	3	12
188	Death and liver transplantation within 2 years of onset of drug-induced liver injury. <i>Hepatology</i> , <b>2017</b> , 66, 1275-1285	11.2	58
187	Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 2134-2146	59.2	361

186	Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1390-1402	6.1	47
185	Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease. <i>Hepatology Research</i> , <b>2017</b> , 47, 1340-1345	5.1	21
184	Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 823-831	3.4	80
183	Gender-Specific Differences in Baseline, Peak, and Delta Serum Creatinine: The NACSELD Experience. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 768-776	4	14
182	All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 115-126	6.1	43
181	The First Six Months Following Liver Transplantation <b>2017</b> , 1079-1092		
180	The Need for Appropriate Comparisons: A Response to Ravi et al. <i>Gastroenterology</i> , <b>2017</b> , 153, 332-333	13.3	1
179	Acute Liver Failure. <i>Clinics in Liver Disease</i> , <b>2017</b> , 21, 769-792	4.6	21
178	Primary Biliary Cholangitis <b>2017</b> , 523-545		
177	Drug Hepatotoxicity: Newer Agents. <i>Clinics in Liver Disease</i> , <b>2017</b> , 21, 115-134	4.6	42
176	A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis. <i>Hepatology</i> , <b>2017</b> , 65, 217-224	11.2	55
175	Hepatic Encephalopathy Is Associated With Mortality in Patients With Cirrhosis Independent of Other Extrahepatic Organ Failures. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 565-574.e4	6.9	69
174	An Immunoassay to Rapidly Measure Acetaminophen Protein Adducts Accurately Identifies Patients With Acute Liver Injury or Failure. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 555-562.e3	6.9	45
173	Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx012	1	4
172	Acute-on-Chronic Liver Failure <b>2017</b> , 432-459		
171	Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. <i>BMJ Open Diabetes Research and Care</i> , <b>2017</b> , 5, e000400	4.5	13
170	Viral Hepatitis: Hepatitis C <b>2017</b> , 143-163		
169	Letter: should HCV cirrhotics with high bilirubin or Gilbert syndrome be excluded from paritaprevir, ombitasvir, or dasabuvir? Authors Reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 1022-3	6.1	

168	On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial. <i>Antiviral Therapy</i> , <b>2016</b> , 21, 541-546	1.6	6
167	Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 1297-304 <sup>0.7</sup>	0.7	32
166	Reply. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 918-919	6.9	
165	Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 674-96	6.1	107
164	Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. <i>Gastroenterology</i> , <b>2016</b> , 150, 1590-1598	13.3	219
163	Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. <i>Hepatology</i> , <b>2016</b> , 63, 437-44	11.2	53
162	Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. <i>Gastroenterology</i> , <b>2016</b> , 150, 1579-1589.e2	13.3	141
161	Hepatitis E Virus Does Not Contribute to Hepatic Decompensation Among Patients With Advanced Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 896-902	6.9	5
160	Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 283-91.e5	2.4	43
159	Association Between Plasma Level of Galectin-9 and Survival of Patients With Drug-Induced Acute Liver Failure. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 606-612.e3	6.9	12
158	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , <b>2016</b> , 150, 419-29	13.3	140
157	Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 5285-92	5.6	8
156	Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 9613-9622	5.6	6
155	Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. <i>PLoS ONE</i> , <b>2016</b> , 11, e0151703	3.7	5
154	Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy. <i>Journal of Viral Hepatitis</i> , <b>2016</b> , 23, 408-18	3.4	56
153	Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States. <i>Liver Transplantation</i> , <b>2016</b> , 22, 505-15	4.5	53
152	Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. <i>Liver Transplantation</i> , <b>2016</b> , 22, 446-58	4.5	66
151	The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. <i>Hepatology</i> , <b>2016</b> , 64, 200-8	11.2	137

150	Outcomes in Adults With Acute Liver Failure Between 1998 and 2013: An Observational Cohort Study. <i>Annals of Internal Medicine</i> , <b>2016</b> , 164, 724-32	8	188
149	Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. <i>Liver Transplantation</i> , <b>2016</b> , 22, 24-33	4.5	96
148	Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1035-43	6.9	97
147	Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. <i>Gastroenterology</i> , <b>2016</b> , 151, 893-901.e1	13.3	43
146	Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 134-44	6.1	49
145	Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of HyQ Law and a New Prognostic Model. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 2360-8	6.9	43
144	Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2015</b> , 9, 547-58	4.2	19
143	Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. <i>Hepatology</i> , <b>2015</b> , 62, 25-30	11.2	71
142	Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1728-35	27.4	78
141	Grazoprevir-Elbasvir Combination Therapy for Treatment-Naïve Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. <i>Annals of Internal Medicine</i> , <b>2015</b> , 163, 1-13	8	425
140	Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. <i>Hepatology</i> , <b>2015</b> , 62, 79-86	11.2	207
139	Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naïve and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. <i>Lancet, The</i> , <b>2015</b> , 385, 2502-9	40	220
138	Hepatitis C Genotype 3: The Remaining Problem. <i>Current Hepatology Reports</i> , <b>2015</b> , 14, 267-273	1	
137	Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1301-8	4	4
136	Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. <i>Gastroenterology</i> , <b>2015</b> , 148, 1353-61.e3	13.3	67
135	Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 1450-9	0.7	71
134	Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 753-9.e1-2	6.9	81
133	Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. <i>Lancet Infectious Diseases, The</i> , <b>2015</b> , 15, 27-35	25.5	52

132	Diagnosis and management of overlap syndromes. <i>Clinics in Liver Disease</i> , <b>2015</b> , 19, 81-97	4.6	23
131	American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. <i>Gastroenterology</i> , <b>2015</b> , 148, 215-9; quiz e16-7	13.3	390
130	Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 286-93	13.4	74
129	Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 258-72	6.1	36
128	T1ρMRI of healthy and fibrotic human livers at 1.5T. <i>Journal of Translational Medicine</i> , <b>2015</b> , 13, 292	8.5	28
127	High risk of delisting or death in liver transplant candidates following infections: Results from the North American Consortium for the Study of End-Stage Liver Disease. <i>Liver Transplantation</i> , <b>2015</b> , 21, 881-8	4.5	47
126	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. <i>Gastroenterology</i> , <b>2015</b> , 149, 649-59	13.3	622
125	Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2618-28	59.2	558
124	A cut-off serum creatinine value of 1.5 mg/dl for AKI--to be or not to be. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 741-3	13.4	23
123	Supplements and Hepatotoxicity. <i>Gastroenterology and Hepatology</i> , <b>2015</b> , 11, 477-9	0.7	
122	Transjugular intrahepatic portosystemic shunts in liver transplant recipients. <i>Liver Transplantation</i> , <b>2014</b> , 20, 130-9	4.5	14
121	Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. <i>Hepatology</i> , <b>2014</b> , 60, 250-6	11.2	317
120	Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 1879-88	59.2	975
119	Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 1483-93	59.2	1122
118	ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 1983-92	59.2	594
117	Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 211-21	59.2	956
116	Hepatitis B and C in African Americans: current status and continued challenges. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 738-48	6.9	32
115	Review article: HCV genotype 3 --the new treatment challenge. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 686-98	6.1	93

114	Drug-induced liver injury due to cancer chemotherapeutic agents. <i>Seminars in Liver Disease</i> , <b>2014</b> , 34, 162-71	7.3	37
113	End-stage renal disease after liver transplantation in patients with pre-transplant chronic kidney disease. <i>Clinical Transplantation</i> , <b>2014</b> , 28, 205-10	3.8	17
112	Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. <i>Gastroenterology</i> , <b>2014</b> , 147, 96-108.e4	13.3	142
111	Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 1550-5	6.9	29
110	Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances. <i>Journal of Clinical and Translational Hepatology</i> , <b>2014</b> , 2, 124-133	5.2	17
109	Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances. <i>Journal of Clinical and Translational Hepatology</i> , <b>2014</b> , 2, 124-33	5.2	13
108	Budd-Chiari syndrome: a single-center experience. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 16236-44.6	4.6	23
107	NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , <b>2013</b> , 22, 1337-46	5.9	27
106	Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation. <i>Hepatology</i> , <b>2013</b> , 58, 1181-4	11.2	7
105	Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. <i>Gastroenterology</i> , <b>2013</b> , 145, 1035-1044.e5	13.3	42
104	New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. <i>Gastroenterology</i> , <b>2013</b> , 145, 1280-8.e1	13.3	175
103	Acetaminophen-related hepatotoxicity. <i>Clinics in Liver Disease</i> , <b>2013</b> , 17, 587-607, viii	4.6	175
102	Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. <i>Lancet Infectious Diseases</i> , <b>2013</b> , 13, 401-8	25.5	281
101	Review article: herbal and dietary supplement hepatotoxicity. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 3-17	6.1	190
100	Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , <b>2013</b> , 22, 527-36	5.9	62
99	Letter: retrospective reviews of liver-related case reports allegedly associated with Herbalife present insufficient and inaccurate data--authors'Reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 754-5	6.1	4
98	Factors that predict short-term intensive care unit mortality in patients with cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2013</b> , 11, 1194-1200.e2	6.9	17
97	Sofosbuvir for previously untreated chronic hepatitis C infection. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 1878-87	59.2	1380

96	Chronic kidney disease after liver transplantation in human immunodeficiency virus/hepatitis C virus-coinfected recipients versus human immunodeficiency virus-infected recipients without hepatitis C virus: results from the National Institutes of Health multi-site study. <i>Liver Transplantation</i> , <b>2013</b> , 19, 419-26.	4.5	5
95	Intensified peginterferon 2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein. <i>Journal of Clinical Gastroenterology</i> , <b>2013</b> , 47, 271-9	3	2
94	Underreporting of liver transplant waitlist removals due to death or clinical deterioration: results at four major centers. <i>Transplantation</i> , <b>2013</b> , 96, 211-6	1.8	33
93	Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 2423-9	4	91
92	Risk factors for hepatocellular carcinoma. <i>Clinical Liver Disease</i> , <b>2012</b> , 1, 180-182	2.2	33
91	Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. <i>Hepatology</i> , <b>2012</b> , 56, 2328-35	11.2	269
90	Pruritus in chronic cholestatic liver disease. <i>Clinics in Liver Disease</i> , <b>2012</b> , 16, 331-46	4.6	42
89	Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. <i>Expert Opinion on Drug Safety</i> , <b>2012</b> , 11, 901-9	4.1	4
88	A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 1012-1018	13.4	32
87	Bacterial infections in end-stage liver disease: current challenges and future directions. <i>Gut</i> , <b>2012</b> , 61, 1219-25	19.2	68
86	Hepatitis C viral infection in patients with cirrhosis. <i>Clinical Liver Disease</i> , <b>2012</b> , 1, 65-68	2.2	
85	Response-guided and -unguided treatment of chronic hepatitis C. <i>Liver International</i> , <b>2012</b> , 32 Suppl 1, 64-73	7.9	11
84	Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 308, 274-82	27.4	103
83	Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C. <i>Clinical Trials</i> , <b>2012</b> , 9, 102-12	2.2	12
82	Hormones: a potential explanation for differences in response rates to therapy for chronic hepatitis C infection. <i>Gastroenterology</i> , <b>2011</b> , 140, 776-9	13.3	3
81	Boceprevir for untreated chronic HCV genotype 1 infection. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 1195-206	59.2	2074
80	Telaprevir for previously untreated chronic hepatitis C virus infection. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 2405-16	59.2	2004
79	Acute-on-chronic liver failure before liver transplantation: impact on posttransplant outcomes. <i>Transplantation</i> , <b>2011</b> , 92, 952-7	1.8	57

78	Chronic kidney disease after orthotopic liver transplantation: impact of hepatitis C infection. <i>Transplantation</i> , <b>2011</b> , 91, 1245-9	1.8	4
77	Ribavirin: How Does it Work and is it Still Needed?. <i>Current Hepatitis Reports</i> , <b>2011</b> , 10, 168-178		7
76	Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2011</b> , 20, 689-99	2.6	105
75	Liver Biopsy and Laparoscopy <b>2011</b> , 44-57		
74	Immune dysfunction and infections in patients with cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2011</b> , 9, 727-38	6.9	233
73	Effect of kidney transplantation on outcomes among patients with hepatitis C. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2011</b> , 22, 1152-60	12.7	112
72	Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. <i>Journal of Clinical Pharmacology</i> , <b>2010</b> , 50, 434-49	2.9	102
71	Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. <i>Gastroenterology</i> , <b>2010</b> , 139, 1602-11, 1611.e1	13.3	91
70	Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. <i>Gastroenterology</i> , <b>2010</b> , 139, 1972-83	13.3	28
69	Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. <i>Liver Transplantation</i> , <b>2009</b> , 15, 1010-20	4.5	21
68	Outcomes after liver transplantation: chronic kidney disease. <i>Liver Transplantation</i> , <b>2009</b> , 15 Suppl 2, S70-4	4.5	64
67	Management of HBV, HCV, and HDV coinfection. <i>Current Hepatitis Reports</i> , <b>2009</b> , 8, 111-118		
66	Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. <i>Journal of Viral Hepatitis</i> , <b>2009</b> , 16, 724-31	3.4	39
65	Ribavirin: current role in the optimal clinical management of chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2009</b> , 50, 402-11	13.4	47
64	Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. <i>Gastroenterology</i> , <b>2009</b> , 137, 110-8	13.3	483
63	Hepatitis C virus infection and immunomodulatory therapies. <i>Clinics in Liver Disease</i> , <b>2009</b> , 13, 391-401	4.6	7
62	Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , <b>2009</b> , 7, 104-13	6.9	100
61	Current management of hepatocellular carcinoma. <i>Medical Clinics of North America</i> , <b>2009</b> , 93, 885-900, viii	7	45



60	Approach to a liver mass. <i>Clinics in Liver Disease</i> , <b>2009</b> , 13, 193-210	4.6	4
59	Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. <i>Annals of Internal Medicine</i> , <b>2009</b> , 150, 528-40	8	135
58	Diagnosis and treatment of hepatocellular carcinoma. <i>Gastroenterology</i> , <b>2008</b> , 134, 1752-63	13.3	842
57	Rapid virologic response: a new milestone in the management of chronic hepatitis C. <i>Clinical Infectious Diseases</i> , <b>2008</b> , 46, 78-84	11.6	113
56	Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. <i>Journal of Viral Hepatitis</i> , <b>2008</b> , 15, 129-36	3.4	31
55	Transplantation: impact of pretransplant renal insufficiency. <i>Liver Transplantation</i> , <b>2008</b> , 14, 665-71	4.5	72
54	Ribavirin considerations in treatment optimization. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 23-30	1.6	13
53	Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. <i>Clinical Gastroenterology and Hepatology</i> , <b>2007</b> , 5, 124-9	6.9	382
52	Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation. <i>Clinical Transplantation</i> , <b>2007</b> , 21, 377-84	3.8	30
51	Coagulopathy in liver disease. <i>Current Treatment Options in Gastroenterology</i> , <b>2007</b> , 10, 464-73	2.5	35
50	Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 2196-205	0.7	99
49	Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 880-9	0.7	77
48	Virological response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alpha-2a: a randomized, phase 2 study. <i>Journal of Hepatology</i> , <b>2007</b> , 47, 51-9	13.4	41
47	Evaluation of nonmalignant liver masses. <i>Current Gastroenterology Reports</i> , <b>2006</b> , 8, 38-45	5	9
46	Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. <i>Hepatology</i> , <b>2006</b> , 43, 954-60	11.2	412
45	Benign Lesions of the Liver. <i>Gastroenterology and Hepatology</i> , <b>2006</b> , 2, 325-326	0.7	
44	Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. <i>Journal of Hepatology</i> , <b>2005</b> , 43, 425-33	13.4	425
43	Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy. <i>Hepatology</i> , <b>2005</b> , 42, 635-40	11.2	52

42	Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. <i>Liver Transplantation</i> , <b>2005</b> , 11, 1048-55	4.5	133
41	Hepatocellular carcinoma: current treatment strategies. <i>Current Treatment Options in Gastroenterology</i> , <b>2005</b> , 8, 457-66	2.5	9
40	Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD). <i>Seminars in Liver Disease</i> , <b>2004</b> , 24 Suppl 2, 33-8	7.3	40
39	Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. <i>Hepatology</i> , <b>2004</b> , 40, 892-899	11.2	63
38	Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. <i>Hepatology</i> , <b>2004</b> , 39, 1702-8	11.2	234
37	Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. <i>Journal of Hepatology</i> , <b>2004</b> , 41, 1062-4	13.4	85
36	The North American Study for the Treatment of Refractory Ascites. <i>Gastroenterology</i> , <b>2003</b> , 124, 634-41	13.3	334
35	Hepatotoxicity of hypolipidemic drugs. <i>Clinics in Liver Disease</i> , <b>2003</b> , 7, 415-33	4.6	63
34	Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes. <i>Clinics in Liver Disease</i> , <b>2003</b> , 7, 683-714	4.6	15
33	Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. <i>Advanced Drug Delivery Reviews</i> , <b>2002</b> , 54, 571-86	18.5	192
32	Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , <b>2002</b> , 9, 334-9	3.4	37
31	Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 2117-9	0.7	100
30	Hand-assisted laparoscopic microwave coagulation therapy for hepatocellular carcinoma. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2002</b> , 16, 717-717	5.2	
29	Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. <i>New England Journal of Medicine</i> , <b>2002</b> , 347, 975-82	59.2	5551
28	Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). <i>Journal of Hepatology</i> , <b>2002</b> , 37, 500-6	13.4	337
27	Dilatation of biliary strictures through the afferent limb of a Roux-en-Y choledochojejunostomy in patients with sclerosing cholangitis. <i>World Journal of Surgery</i> , <b>2001</b> , 25, 1251-3	3.3	7
26	Extrahepatic manifestations of chronic viral hepatitis. <i>Current Gastroenterology Reports</i> , <b>2001</b> , 3, 71-8	5	69
25	Glutathione-S-Transferase M1 null genotype in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2001</b> , 46, 2080-3	4	4

24	Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. <i>Hepatology</i> , <b>2001</b> , 33, 433-8	11.2	269
23	Large cystic lesions of the liver in adults: a 15-year experience in a tertiary center. <i>Journal of the American College of Surgeons</i> , <b>2001</b> , 193, 36-45	4.4	103
22	Severe liver injury. <i>Annals of Internal Medicine</i> , <b>2001</b> , 135, 550	8	6
21	Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. <i>American Surgeon</i> , <b>2001</b> , 67, 173-8	0.8	112
20	Transplantation for chronic hepatitis B and C: strategies for prevention and treatment of recurrent disease. <i>Indian Journal of Gastroenterology</i> , <b>2001</b> , 20 Suppl 1, C59-63	1.9	
19	Chronic graft-versus-host disease of the liver: presentation as an acute hepatitis. <i>Hepatology</i> , <b>2000</b> , 32, 1265-71	11.2	92
18	Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. <i>Annals of Pharmacotherapy</i> , <b>2000</b> , 34, 915-23	2.9	145
17	Amebiasis. <i>Current Treatment Options in Gastroenterology</i> , <b>1999</b> , 2, 97-103	2.5	8
16	Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. <i>Hepatology</i> , <b>1999</b> , 30, 787-93	11.2	269
15	Hepatitis C virus genotypes and viremia and hepatocellular carcinoma in the United States. <i>American Journal of Gastroenterology</i> , <b>1999</b> , 94, 1619-26	0.7	34
14	Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. <i>Clinical and Experimental Metastasis</i> , <b>1997</b> , 15, 509-18	4.7	45
13	Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. <i>Annals of Internal Medicine</i> , <b>1996</b> , 125, 634-9	8	271
12	Absence of anti-LKM-1 antibody in hepatitis C viral infection in the United States of America. <i>Journal of Viral Hepatitis</i> , <b>1995</b> , 2, 175-9	3.4	39
11	Hepatotoxicity of antimicrobial, antifungal, and antiparasitic agents. <i>Gastroenterology Clinics of North America</i> , <b>1995</b> , 24, 923-36	4.4	5
10	Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas. <i>Cancer</i> , <b>1994</b> , 74, 1869-73	6.4	9
9	Approach to a liver mass. <i>Seminars in Liver Disease</i> , <b>1993</b> , 13, 423-35	7.3	59
8	Viral pathogenesis of hepatocellular carcinoma in the United States. <i>Hepatology</i> , <b>1993</b> , 18, 1326-1333	11.2	108
7	Viral pathogenesis of hepatocellular carcinoma in the United States. <i>Hepatology</i> , <b>1993</b> , 18, 1326-33	11.2	103

6	Amoxicillin-clavulanate potassium-associated cholestasis. <i>Gastroenterology</i> , <b>1989</b> , 96, 1135-41	13.3	83
5	Hepatic encephalopathy and orotic aciduria associated with hepatocellular carcinoma in a noncirrhotic liver. <i>Hepatology</i> , <b>1988</b> , 8, 78-81	11.2	16
4	Combined surgical and radiologic approach to recurrent cholangitis and intrahepatic pigment stones. <i>Gastroenterology</i> , <b>1988</b> , 95, 1383-7	13.3	3
3	Spontaneous group B Salmonella enteritidis peritonitis in cirrhotic ascites and acquired immune deficiency syndrome. <i>American Journal of Gastroenterology</i> , <b>1988</b> , 83, 882-4	0.7	10
2	Electron microscopic evidence of non-A, non-B hepatitis markers and virus-like particles in immunocompromised humans. <i>Hepatology</i> , <b>1984</b> , 4, 628-32	11.2	15
1	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. <i>Nature Genetics</i> ,	36.3	2